Log in

REGENXBIO Stock Forecast, Price & News

+1.39 (+5.13 %)
(As of 10/22/2020 12:00 AM ET)
Today's Range
Now: $28.50
50-Day Range
MA: $28.28
52-Week Range
Now: $28.50
Volume449,285 shs
Average Volume425,925 shs
Market Capitalization$1.06 billion
P/E RatioN/A
Dividend YieldN/A
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:RGNX



Sales & Book Value

Annual Sales$35.23 million
Book Value$12.23 per share


Net Income$-94,730,000.00
Net Margins-222.24%


Market Cap$1.06 billion
Next Earnings Date11/3/2020 (Estimated)
+1.39 (+5.13 %)
(As of 10/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

How has REGENXBIO's stock price been impacted by COVID-19?

REGENXBIO's stock was trading at $32.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RGNX shares have decreased by 13.3% and is now trading at $28.50.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of REGENXBIO?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for REGENXBIO

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for REGENXBIO

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.89) by $0.02. The biotechnology company had revenue of $16.60 million for the quarter, compared to analysts' expectations of $22.23 million. REGENXBIO had a negative return on equity of 31.06% and a negative net margin of 222.24%. The business's revenue for the quarter was up 110.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.04) earnings per share.
View REGENXBIO's earnings history

What price target have analysts set for RGNX?

7 equities research analysts have issued 12 month price objectives for REGENXBIO's shares. Their forecasts range from $42.00 to $95.00. On average, they anticipate REGENXBIO's share price to reach $66.00 in the next year. This suggests a possible upside of 131.6% from the stock's current price.
View analysts' price targets for REGENXBIO

Who are some of REGENXBIO's key competitors?

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), Crispr Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:
  • Mr. Kenneth T. Mills, CEO, Pres & Director (Age 45, Pay $986.83k)
  • Mr. Vittal K. Vasista, Chief Financial Officer (Age 52, Pay $636.48k)
  • Mr. Patrick J. Christmas II, Chief Legal Officer (Age 49, Pay $610.82k)
  • Dr. Olivier Danos, Chief Scientific Officer (Age 62, Pay $622.73k)
  • Dr. Stephen Pakola, Chief Medical Officer (Age 51, Pay $549.77k)

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a number of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%), Louisiana State Employees Retirement System (0.04%), Exane Derivatives (0.01%), Exane Derivatives (0.01%), Nisa Investment Advisors LLC (0.01%) and Pacer Advisors Inc. (0.01%). Company insiders that own REGENXBIO stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista.
View institutional ownership trends for REGENXBIO

Which institutional investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold REGENXBIO company stock in the last year include Curran Simpson, Donald J Hayden Jr, and Vittal Vasista.
View insider buying and selling activity for REGENXBIO

Which institutional investors are buying REGENXBIO stock?

RGNX stock was bought by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Pacer Advisors Inc., Nisa Investment Advisors LLC, Exane Derivatives, and Exane Derivatives.
View insider buying and selling activity for REGENXBIO

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $28.50.

How big of a company is REGENXBIO?

REGENXBIO has a market capitalization of $1.06 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. REGENXBIO employs 257 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is www.regenxbio.com.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]

This page was last updated on 10/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.